In a dual‑energy X‑ray absorptiometry (DEXA) report for osteoporosis screening, does the phrase “there has been a decrease in the interval” indicate that the patient’s bone density is worsening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, "a decrease in the interval" on a DEXA report means worsening bone density.

When a DEXA report states "there has been a decrease in the interval," this indicates that bone mineral density (BMD) has declined between the current scan and the previous scan, representing a worsening of bone health.

Understanding the Terminology

The phrase "decrease in the interval" refers to a reduction in BMD measured between two time points. However, this statement alone is insufficient for clinical decision-making—you must determine whether this decrease is:

  • Statistically significant (exceeds the Least Significant Change)
  • Clinically meaningful (warrants action)
  • Real versus artifact (technical error vs. true biological change)

Critical Evaluation Steps

1. Verify Statistical Significance

The reported decrease must exceed the Least Significant Change (LSC) to be considered a true change 1. The LSC values in g/cm² should be stated in the DEXA report. Any "change" that doesn't exceed the LSC is not a real change at all 1.

2. Assess for Technical Errors

You should suspect technical or interpretation errors when 1:

  • BMD changes exceed 10% over 1-2 years (rule of thumb based on expert opinion)
  • Changes exceed expected physiologic changes for the clinical scenario
  • The patient has been on stable osteoporosis therapy
  • Different scanners or anatomic sites were used between scans

Common technical errors include 1, 2:

  • Incorrect patient positioning
  • Improper scan analysis
  • Errors in bone edge detection
  • Incorrect intervertebral marker placement
  • Use of different anatomic sites for comparison

3. Determine Clinical Context

When a significant decrease occurs in patients receiving osteoporosis therapy, investigate 1:

  • Technical scanning errors (review actual images, not just the report)
  • Secondary causes of bone loss (new medications, medical conditions)
  • Medication compliance (especially oral bisphosphonates)
  • Drug absorption issues (concomitant calcium supplements, multivitamins, other medications)

Site-Specific Considerations

Total hip BMD change provides the most robust indication of treatment effect and fracture risk, whereas spine BMD change is not independently associated with fracture risk 3. When monitoring treatment:

  • A detectable decrease in total hip BMD increases major osteoporotic fracture risk (adjusted HR 1.46)
  • A detectable increase in total hip BMD decreases fracture risk (adjusted HR 0.71)
  • These associations hold for hip and clinical vertebral fractures 3

Common Pitfalls

DXA reports should NOT include 1:

  • Any statement about bone loss unless there is a prior scan for comparison
  • Commentary about BMD change when the difference doesn't exceed the LSC
  • Gradation of osteopenia (mild, moderate, severe)

Spine BMD can be falsely elevated by 4:

  • Degenerative changes (osteophytes, facet sclerosis)
  • Disk space narrowing
  • Spondylosis
  • Compression fractures

This can mask true bone loss, particularly in elderly patients where spine measurements become less reliable.

Action Algorithm

When you see "decrease in the interval":

  1. Confirm the decrease exceeds the LSC (if not stated, request clarification)
  2. Review the actual scan images, not just the report interpretation 1
  3. If decrease >10% over 1-2 years: Scrutinize for technical errors 1
  4. If patient is on treatment: Investigate compliance, absorption issues, and secondary causes 1
  5. Consider re-evaluation when changes are outside expected range for the clinical scenario 5
  6. Prioritize total hip measurements over spine for monitoring treatment response 3

The phrase indicates worsening, but you must verify it represents true biological change rather than technical artifact before making treatment decisions.

References

Guideline

consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the quality of dxa scans and reports.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2018

Research

Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2004

Research

Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019

Guideline

updated practice guideline for dual-energy x-ray absorptiometry (dxa).

European Journal of Nuclear Medicine and Molecular Imaging, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.